Biotechnology, Pharmaceuticals, and Research by Crinetics Pharmaceuticals

  • Ciaran Ryan
  • 10.06.2026
Crinetics Pharmaceuticals stock rebounds 4.45% as Everyday Advocacy launch highlights patient support, Crinetics
Crinetics Pharmaceuticals launched Everyday Advocacy to support patients living with complex endocrine conditions. The company made the announcement in a recent tweet.Crinetics Pharmaceuticals ...
  • Ezequiel Gomes
  • 03.06.2026
Crinetics stock falls 5.94 percent as shares face renewed selling pressure, Crinetics
Crinetics Pharmaceuticals stated that advocacy for many patients occurs in everyday moments through conversations, symptom management, and questions.Crinetics Pharmaceuticals said having the right ...
  • Andreas Kristo
  • 11.03.2026
Systematic review on acromegaly therapies receives journal approval, Crinetics Pharmaceuticals announces
Crinetics Pharmaceuticals announced that its systematic literature review and network meta-analysis of pharmacologic therapies for acromegaly has been accepted for publication in the Journal of ...
  • Viktoras Karapetjanc
  • 03.12.2025
Crinetics Pharmaceuticals doses first patient in novel tumor treatment trial
Crinetics Pharmaceuticals has announced a significant milestone with the dosing of the first patient in their Phase 1/2 trial. The trial is focused on evaluating CRN09682, a novel nonpeptide drug ...